John A. Kanis named winner of IOF Olof Johnell Science Award
Prestigious award recognizes one of the bone field’s most distinguished researchers for his achievements in musculoskeletal research and policy implementation
The 2019 International Osteoporosis Foundation (IOF) Olof Johnell Science Award was presented to Professor John A. Kanis at a ceremony held on April 4 at the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Paris, France.
The Award recognizes extraordinary and internationally recognized contributions to the field of osteoporosis in a scientific or policy implementation area. It is named in honour of the late Olof Johnell, a Swedish orthopaedic surgeon and researcher who made major and lasting contributions to the field of osteoporosis and to the work of IOF.
In presenting the award, IOF President Cyrus Cooper stated:
“As an immensely impactful investigator and advocate for osteoporosis and fracture prevention, John Kanis is a leader of the bone field. His stellar career has included involvement in the densitometric definition of osteoporosis and ground-breaking research in the epidemiology of fracture risk. His development of FRAX models to calculate absolute fracture risk has essentially changed clinical practice. It is therefore an honour to present this, IOF’s most prestigious science award, to such an exceptional investigator and advocate of the bone field.”
Prof. John A. Kanis is Emeritus Professor in Human Metabolism, and Director of the Centre for Metabolic Bone Diseases (formerly WHO Collaborating Centre), University of Sheffield, UK and Professorial Fellow at the Australian Catholic University, Melbourne, Australia. He is the Honorary President of the International Osteoporosis Foundation, member of the IOF Committee of Scientific Advisors and Chairman of the Working Group on Epidemiology and Quality of Life. He is Honorary President of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Prof. Kanis’ research focus is largely related to disorders of skeletal metabolism including osteoporosis, sarcopenia, Paget’s disease of bone, hyperparathyroidism, renal osteodystrophy and neoplasia affecting the skeleton. Contributions to research include cell biology, histomorphometry of bone, assessment and treatment of bone disorders, guideline development, health technology assessment, epidemiology, regulatory affairs and health economics. His current major interest is in the development of risk assessment algorithms and the formulation of practice guidelines in many regions of the world.
He is Editor-in-Chief of ‘Osteoporosis International’ and ‘Archives of Osteoporosis’, and serves on the editorial board of several other leading journals. Prof. Kanis is the author of more than 1000 papers, chapters and books on bone disease and metabolism. He is the recipient of numerous awards including the Barter Award for Clinical Sciences (ASBMR, 2005) and the Hamdan Award for Medical Research Excellence- Osteoporosis (2010), among others.
World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Paris 2019):
Held jointly by IOF and ESCEO, the Congress takes place in Paris, France, from April 4-7, 2019. WCO-IOF-ESCEO is the world’s largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. For more information and to view Congress abstracts, visit http://www.
The International Osteoporosis Foundation (IOF) is the world’s largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as more than 240 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. http://www.
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. http://www.